Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/cap.2019.0029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of the initial administration of suvorexant on severe sleep apnea syndrome.
Sleep Biol Rhythms
January 2025
Department of Respiratory Medicine, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192 Japan.
The purpose of this study was to evaluate how the first oral administration of suvorexant affects PSG results in patients with severe obstructive sleep apnea (OSA). Single-center, prospective study conducted in a nonrandomized, uncontrolled, unblinded fashion. Undiagnosed 64 patients with suspected OSA underwent first-night PSG, and 30 patients with severe OSA (Apnea Hypopnea Index [AHI] ≥ 30 events/h) underwent second-night PSG testing after administration of 15 mg suvorexant.
View Article and Find Full Text PDFPreliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study.
J Addict Dis
December 2024
Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
No FDA-approved medications for methamphetamine (MA) use disorder (MUD) are available. Suvorexant (SUVO), a dual orexin receptor antagonist that is FDA approved for insomnia treatment, reduces MA self-administration and MA-induced reinstatement responding in preclinical studies. SUVO may also reduce MA use by targeting substance use risk factors, including insomnia, stress, cue reactivity, and craving.
View Article and Find Full Text PDFCharacteristics of psychiatric patients with nightmares after suvorexant administration: A retrospective study.
Neuropsychopharmacol Rep
March 2025
Division of Clinical Neuroscience, Department of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Aim: Suvorexant is an orexin receptor antagonist (ORA) for the treatment of insomnia. The antagonistic action of suvorexant on orexin receptors is associated with an increase in rapid eye movement (REM) sleep, which can potentially lead to nightmares depending on the patient's condition. However, the precise risk factors for nightmares among patients taking ORAs, such as suvorexant, have yet to be identified.
View Article and Find Full Text PDFThe efficacy and safety of dual orexin receptor antagonists in obstructive sleep apnea: A systematic review and meta-analysis of randomised controlled trials.
J Sleep Res
November 2024
Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Dual orexin receptor antagonists (DORAs) are indicated for the treatment of insomnia disorder. However, DORAs may change sleep parameters, thus having adverse effects on patients with obstructive sleep apnea (OSA). This meta-analysis clarified the impact of DORAs in OSA treatment on sleep architecture and respiratory parameters.
View Article and Find Full Text PDFEffects of Approved Pharmacological Interventions for Insomnia on Mood Disorders: A Systematic Review.
Clin Neuropsychiatry
October 2024
Department of Surgical, Medical and Molecular Pathology, Critical and Care Medicine, University of Pisa, Pisa, Italy, Department of Neuroscience, Azienda Ospedaliera Universitaria Pisana (AUOP), Pisa, Italy.
Objective: Insomnia can be a contributing factor, a comorbid disorder, or a transdiagnostic element to several mental disorders, including mood disorders (MDs). A recent meta-analysis has already shown the effectiveness of cognitive behavioral treatment (CBT) for insomnia that is comorbid with MDs. This work aimed to systematically review data on pharmacological insomnia treatment in the context of MDS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!